IRIS
MONNO, Laura
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.118
AS - Asia 4.153
EU - Europa 3.025
SA - Sud America 1.229
AF - Africa 228
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 3
AN - Antartide 1
Totale 20.763
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.010
SG - Singapore 1.686
BR - Brasile 1.064
CN - Cina 929
HK - Hong Kong 848
DE - Germania 603
SE - Svezia 497
IT - Italia 443
RU - Federazione Russa 387
UA - Ucraina 340
VN - Vietnam 269
FI - Finlandia 257
GB - Regno Unito 218
CI - Costa d'Avorio 132
IN - India 84
ID - Indonesia 69
AR - Argentina 63
BE - Belgio 55
BD - Bangladesh 54
FR - Francia 42
IE - Irlanda 42
CA - Canada 40
MX - Messico 39
ZA - Sudafrica 33
EC - Ecuador 32
TR - Turchia 30
IQ - Iraq 27
PL - Polonia 25
AT - Austria 22
PK - Pakistan 21
JP - Giappone 20
CO - Colombia 18
NL - Olanda 18
KE - Kenya 14
VE - Venezuela 14
ES - Italia 12
IR - Iran 12
PY - Paraguay 12
SA - Arabia Saudita 12
DZ - Algeria 11
GR - Grecia 11
IL - Israele 11
HR - Croazia 10
MA - Marocco 10
JO - Giordania 9
LT - Lituania 9
UZ - Uzbekistan 9
EG - Egitto 8
PE - Perù 8
UY - Uruguay 8
AE - Emirati Arabi Uniti 7
TN - Tunisia 7
CL - Cile 6
HN - Honduras 6
PH - Filippine 6
RS - Serbia 6
AZ - Azerbaigian 5
BG - Bulgaria 5
CR - Costa Rica 5
KZ - Kazakistan 5
LB - Libano 5
NP - Nepal 5
CH - Svizzera 4
DO - Repubblica Dominicana 4
GE - Georgia 4
HU - Ungheria 4
TT - Trinidad e Tobago 4
AL - Albania 3
CZ - Repubblica Ceca 3
EU - Europa 3
GY - Guiana 3
KR - Corea 3
OM - Oman 3
PA - Panama 3
PT - Portogallo 3
SN - Senegal 3
TW - Taiwan 3
AU - Australia 2
BH - Bahrain 2
BW - Botswana 2
GH - Ghana 2
KG - Kirghizistan 2
KW - Kuwait 2
MW - Malawi 2
NI - Nicaragua 2
PS - Palestinian Territory 2
XK - ???statistics.table.value.countryCode.XK??? 2
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
AQ - Antartide 1
BB - Barbados 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CW - ???statistics.table.value.countryCode.CW??? 1
DK - Danimarca 1
EE - Estonia 1
GF - Guiana Francese 1
GM - Gambi 1
GT - Guatemala 1
JM - Giamaica 1
Totale 20.748
Salva come PNG Salva come JPEG
Città #
Fairfield 1.825
Woodbridge 1.179
Ashburn 1.117
Hong Kong 846
Singapore 828
Chandler 815
Houston 789
Jacksonville 767
Seattle 718
Wilmington 619
Cambridge 598
Ann Arbor 454
Nyköping 366
Beijing 286
Roxbury 227
Lawrence 225
Nanjing 204
New York 163
Princeton 142
Abidjan 132
Boardman 131
Des Moines 123
Los Angeles 108
Dallas 100
São Paulo 94
San Diego 77
Bari 74
Munich 72
Ho Chi Minh City 66
Dong Ket 65
Inglewood 65
Shenyang 64
Santa Clara 63
Helsinki 56
Hanoi 53
Buffalo 50
Nanchang 50
Brooklyn 49
Hebei 49
Jakarta 47
London 45
Dublin 42
Rio de Janeiro 41
Milan 35
Brussels 34
Jiaxing 34
Rome 34
Tianjin 34
The Dalles 27
Columbus 26
Chicago 24
Nuremberg 22
Moscow 21
Curitiba 20
Turku 20
Belo Horizonte 19
Council Bluffs 19
Taranto 19
Tokyo 19
Warsaw 19
Changsha 18
Johannesburg 18
Paris 18
Mexico City 17
Norwalk 16
Brasília 15
Campinas 15
Falls Church 15
Pune 15
San Francisco 15
Toronto 14
Denver 13
Boston 12
Nairobi 12
Atlanta 11
Guangzhou 11
Montreal 11
Mumbai 11
Porto Alegre 11
Quito 11
Recife 11
Bauru 10
Chennai 10
Guarulhos 10
Guayaquil 10
Stockholm 10
Washington 10
Baghdad 9
Dearborn 9
Dhaka 9
Lahore 9
Redwood City 9
Zagreb 9
Amman 8
Bergamo 8
Fortaleza 8
Franca 8
Istanbul 8
Osasco 8
Salvador 8
Totale 14.770
Salva come PNG Salva come JPEG
Nome #
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 354
Influence of HLA-B18 on liver fibrosis progression in a cohort of HIV/HCV coinfected individuals 341
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV 200
Access to health services for undocumented immigrants in Apulia. 184
Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART 170
HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ? 167
Variability OF HIV-1 V2 env domain for integrin binding: Clinical correlates 165
HIV-RNA decay in paired blood and semen samples of subjects receiving their first dolutegravir-based ART regimen 162
An outbreak of HIV-1 BC recombinants in Southern Italy 159
Aeromonas sobria sepsis complicated by rhabdomyolysis in an HIV-positive patient: case report and evaluation of traits associated with bacterial virulence 158
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: A multicenter retrospective cohort study from 2007 to 2015 153
Cerebrospinal fluid compartmentalization of HIV-1 and correlation with plasma viral load and blood–brain barrier damage 153
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. 151
Potential diagnostic properties of chest ultrasound in thoracic tuberculosis—A systematic review 151
An intricate case of multidrug resistant Plasmodium falciparum isolate imported from Cambodia 148
Aeromonas sobria sepsis complicated by rhabdomyolysis in an HIV-positive patient: case report and evaluation of traits associated with bacterial virulence 147
Amoebic hepatic abscesses in an HIV-positive patient 143
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 142
Comment on: Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute/recent HIV infection 142
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study 141
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 141
Chronic Inflammation in a Long-Term Cohort of HIV-Infected Patients According to the Normalization of the CD4:CD8 Ratio 139
The elderly and direct antiviral agents: Constraint or challenge? 139
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 138
Co-receptor switch during HAART is independent of virological success 136
Prevalence of urinary schistosomiasis in migrants in Apulia, a region of southern Italy, in the years 2006-2016 136
Reduced community viral load does not coincide with a reduction in the rate of new HIV diagnoses and recent infections: data from a region of southern Italy 136
Local epidemics gone viral: Evolution and diffusion of the Italian HIV-1 recombinant form CRF60_BC 135
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 135
Improved virological outcome in non-B patients: a possible role for baseline coreceptor tropism 134
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 133
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 133
Access to Health Services for Undocumented Immigrants in Apulia 132
Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: data from the Icona Foundation cohort. 132
Cryoglobulinemia in subjects with HCV infection alone, HIV infection and HCV/HIV coinfection 131
HIV tropism and its relationship with transmitted resistance in naive patients 130
Prevalence and Clinical Characteristics of Mycobacterial Diseases in the Barletta-Andria-Trani Province, Italy (2005-2013) 129
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 129
Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies 126
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA <50 cp/mL 126
Prevalence of diabetes mellitus in newly diagnosed pulmonary tuberculosis in Beira, Mozambique 126
Social determinants of therapy failure and multi drug resistance among people with tuberculosis: A review 125
HIV-1 coreceptor tropism: A syllogistic connection with the veterans aging cohort study index and the CD4/CD8 ratio 125
Limiting severe outcomes and impact on intensive care units of moderate-intermediate 2009 pandemic influenza: role of infectious diseases units. 124
Liver abscess due to Fusobacterium necrophorum in an immunocompetent patient 123
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort). 123
HIV-1 biological phenotype and predicted coreceptor usage based on V3 loop sequence in paired PBMC and plasma samples 118
A multidrug-resistant (MDR) HIV type 1 infection in a homosexual man and identified source patient 118
Virological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders. 118
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 118
HIV infection and protease genetic diversity in a rural area of the Southern Central African Republic 116
CD4 and CD4/CD8 ratio progression in HIV-HCV infected patients after achievement of SVR 116
Are the proposed env mutations actually associated with resistance to maraviroc? 116
No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference 116
Risk of severe non AIDS events is increased among patients unable to increase their CD4 + T-cell counts >200+/μl despite effective HAART 115
The at risk child clinic (ARCC): 3 years of health activities in support of the most vulnerable children in Beira, Mozambique 115
Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients. 114
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 114
Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection 113
Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA) 113
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 112
Switch of predicted HIV-1 tropism in treated subjects and its association with disease progression 112
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 112
Reduced concentrations of HIV-RNA and TNF-alpha coexist in CSF of AIDS patients with progressive multifocal leukoencephalopathy 111
Mutational patterns of paired blood and rectal biopsies in HIV-infected patients on HAART 111
Difficulties in classifying a/g recombinants: methodological problems or genetic variability? 110
V3 sequences and paired HIV isolates from 52 non-subtype B HIV type 1-infected patients 110
Tuberculosis and diabetes: Current state and future perspectives 110
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 110
Genotypic analysis of the protease and reverse transcriptase of non-B HIV type 1 clinical isolates from naïve and treated subjects 109
The effect of primary drug resistance on CD4 cell decline and the viral load set-point in HIV positive individuals before the start of antiretroviral therapy. 109
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 108
Focused ultrasound to diagnose HIV-associated tuberculosis (FASH) in the extremely resource-limited setting of South Sudan: a cross-sectional study 107
Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide 107
The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy. 106
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 106
Effects of HIV superinfection on HBV replication in a chronic HbsAg carrier with liver disease 105
Cell cultures from small amounts of heparinized whole blood enhance HIV-1 isolation rate 104
High HIV-1 diversity in immigrants resident in Italy (2008–2017) 104
Response of severe HIV-associated thrombocytopenia to highly active antiretroviral therapy including protease inhibitors 103
Drug Resistance Mutations and Newly Recognized Treatment-Related Substitutions in the HIV-1 Protease Gene: Prevalence and Associations With Drug Exposure and Real or Virtual Phenotypic Resistance to Protease Inhibitors in Two Clinical Cohorts of Antiretroviral Experienced Patients 103
HIV-1 A1 subtype epidemic in Italy originated from Africa and Eastern Europe and shows a high frequency of transmission chains involving intravenous drug users 103
Association between HIV p24 antigen in cerebrospinal fluid and severe complications in the central nervous system 102
Predictors of therapy failure in newly diagnosed pulmonary tuberculosis cases in Beira, Mozambique. 102
Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients 102
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group. 100
Prevalence of mutations and determinants of genotypic resistance to Etravirine (tmc125) in a large Italian resistance database (ARCA) 99
Analisi della cinetica replicativa in cultura primaria di isolati di HIV-1 da soggetti in vario stadio di malattia 99
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 99
Evolution of HIV-1 transmitted drug resistance in Italy in the 2007–2014 period: A weighted analysis 99
Long-term efficacy and safety of TDM-assisted combination of voriconazole plus efavirenz in an AIDS patient with cryptococcosis and liver cirrhosis 98
Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy. 98
HIV-1 resistance to dideoxynucleoside reverse transcriptase inhibitors: genotypic-phenotypic correlations 97
Rapid spread of HTLV-III infection among drug-addicts in Italy 97
Liver abscess due to Fusobacterium necrophorum in an immunocompetent patient. A case report and review of the literature 97
Pathways of care for HIV infected children in Beira, Mozambique: Pre-post intervention study to assess impact of task shifting 97
A rigorous statistical learning method for the estimation and validation of weighted drug susceptibility scores applied to in vivo virological outcome prediction of atazanavir/ritonavir containing HAART 95
Association between HLA class II antigens and hepatitis C virus infection 94
Virological and immunological response to antiretroviral regimens containing maraviroc in HIV type 1-infected patients in clinical practice: role of different tropism testing results and of concomitant treatments. 94
Community-acquired pneumonia 93
Totale 12.701
Salva come PNG Salva come JPEG
Categoria #
all - tutte 90.384
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 90.384
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.353 0 0 0 0 0 103 271 181 216 307 112 163
2021/20221.405 74 166 16 91 60 115 70 113 95 94 199 312
2022/20232.291 409 178 114 204 286 314 25 245 406 19 46 45
2023/2024833 69 163 45 48 71 212 29 21 21 23 30 101
2024/20253.390 41 64 362 121 72 310 251 286 166 176 486 1.055
2025/20263.620 978 555 528 809 643 107 0 0 0 0 0 0
Totale 21.347